Zoptarelin Doxorubicin
A peptide hormone used to carry chemotherapy into cancer cells
Zoptarelin doxorubicin (AEZS-108, formerly AN-152) joins the chemotherapy drug doxorubicin to [D-Lys6]LHRH, a version of the hormone that controls the reproductive axis. Because many endometrial, ovarian, prostate and breast cancers carry LHRH receptors, the idea was to steer doxorubicin into tumour cells. Phase 2 trials showed responses with modest toxicity, but in a 511-patient phase 3 it was not better than doxorubicin alone.
Used in human trials: 267 mg/m², Every 3 weeks, Intravenous infusion (Phase 2: platinum-resistant ovarian cancer) Details ↓
Recommended Dosing
Used in human trials
No manufacturer dose exists for this use: these are amounts given in published trials, not recommendations.
What is it?
Targeted chemotherapy tries to send a toxic drug only where it is needed. Zoptarelin doxorubicin, first called AN-152 and then AEZS-108, links doxorubicin to an LHRH analogue so that cells carrying LHRH receptors take it up. The endometrial trial's report notes that 80% of endometrial cancers express the receptor, and in the ovarian trial 93% of screened tumours did.
The preclinical case was strong across many tumour types. In mice the conjugate inhibited human prostate, breast, pancreatic, bladder and brain tumours that carry LHRH receptors, often where free doxorubicin at the same molar dose did little: 90.5% inhibition of a castration-resistant prostate tumour against 41% for the two parts given separately, and growth of a triple-negative breast tumour that doxorubicin alone did not touch. It also caused less multidrug resistance than doxorubicin in bladder tumours.
The first human study set the dose in 17 women with ovarian, endometrial or breast cancer. Phase 2 trials followed. In 43 women with advanced or recurrent receptor-positive endometrial cancer, 23% responded (5% complete) and 44% had stable disease, with median overall survival of 15 months. In 42 women with platinum-resistant ovarian cancer, 14.3% had partial responses and median survival was 53 weeks, which the authors judged comparable to standard options. In 25 men with castration- and taxane-resistant prostate cancer, 52% were free of progression at 12 weeks.
The decisive test was a phase 3 trial of second-line therapy for endometrial cancer, which enrolled 511 patients and compared the conjugate with free doxorubicin. A 2021 review by the phase 2 investigators reports that it was not superior. That trial did not require tumours to be tested for LHRH receptors, which the reviewers note when calling for better-designed studies.
The doses that reached patients were 267 mg/m² every three weeks in the gynaecological trials and 210 mg/m² in prostate cancer, where neutropenia limited the dose. A pharmacokinetic model built from three human studies predicted no meaningful interaction with statins or metformin through the transporters it blocks in the lab. The mouse work used tumour lines chosen for their LHRH receptors, while the phase 3 trial did not test patients' tumours for them, a gap the phase 2 investigators point to in their review.
Neutropenia and leucopenia were the main serious side effects in phase 2. Zoptarelin doxorubicin was never approved, and later registered trials in breast and urothelial cancer were terminated early.
Mechanism of Action
Zoptarelin doxorubicin is [D-Lys6]LHRH, an LHRH agonist, chemically linked to doxorubicin. Tumour cells with LHRH receptors take up the conjugate, which is meant to concentrate the chemotherapy in them; once released, doxorubicin damages DNA as usual.
Receptor targeting
Uptake through LHRH receptors on endometrial, ovarian, breast, prostate and other tumours.
Doxorubicin
The released drug causes DNA damage and apoptosis.
Less drug resistance (mice)
Triggered less multidrug resistance than free doxorubicin in bladder tumours.
Bone marrow
Neutropenia is the dose-limiting side effect.
Published Research
Studies of zoptarelin doxorubicin, from their PubMed abstracts.
Phase 2 in endometrial cancer
In 43 eligible women with LHRH receptor-positive advanced or recurrent endometrial cancer, 2 (5%) had complete and 8 (18%) partial remissions, 44% stable disease; median time to progression 7 months and overall survival 15 months; grade 3-4 neutropenia 12%, leucopenia 9%.
Phase 2 in platinum-resistant ovarian cancer
Of 42 women given 267 mg/m2 every 3 weeks, 6 (14.3%) had partial responses and 16 (38%) stable disease; median time to progression 12 weeks and overall survival 53 weeks; 93% of screened tumours expressed LHRH receptors.
Phase 2 in resistant prostate cancer
In 25 men with castration- and taxane-resistant prostate cancer given 210 mg/m2 every 3 weeks, 52% were progression-free at 12 weeks without limiting toxicity; median PFS 3.8 months and OS 6.0 months; pain improved in 59%.
First-in-human dose escalation
The first human study of AEZS-108, [D-Lys6]LHRH linked to doxorubicin, enrolled 17 women with metastatic or unresectable ovarian, endometrial or breast cancer to find the maximum tolerated dose and its pharmacokinetics.
Phase 1 in resistant prostate cancer
In men with castration- and taxane-resistant prostate cancer, the maximum tolerated dose was 210 mg/m², limited by persistent neutropenia; three had a PSA response and 9 of 10 evaluable had stable disease.
A pharmacokinetic model and drug interactions
A whole-body model built from three human studies at 10 to 267 mg/m² and from lab data found the conjugate inhibits the transporters OATP1B3 and OCT2 in vitro, but predicted no meaningful change in simvastatin or metformin levels at clinical doses.
Castration-resistant prostate cancer in mice
In mice carrying DU-145 prostate tumours, the conjugate inhibited tumour growth by 90.5% against 41% for the same LHRH analogue and doxorubicin given unlinked. In cells, the conjugate stayed near the membrane and around the nucleus while free doxorubicin entered the nucleus.
Triple-negative breast cancer
LHRH receptors were present in 49% of 69 triple-negative breast cancer specimens. In mice with two such tumour lines, the conjugate inhibited growth while doxorubicin at an equimolar dose did not, and silencing the receptor in cells reduced its effect.
Combined with a glycolysis blocker
In triple-negative breast cancer cells and mice, adding the glycolysis inhibitor 2-deoxyglucose to the conjugate killed more cells and shrank tumours more than either alone.
Pancreatic cancer in mice
LHRH receptors were found on two surgical pancreatic cancer samples and three cell lines; the conjugate strongly inhibited all three tumour lines in mice and beat free doxorubicin on two of them.
Glioblastoma in mice
Glioblastoma samples carried LHRH receptors, and weekly intravenous doses for six weeks reduced U-87 MG tumour growth in mice by 76%, with apoptosis and reduced blood-vessel signalling.
Bladder cancer in mice
LHRH receptors were present on 18 clinical bladder cancers and four cell lines. In mice the conjugate inhibited these tumours more than doxorubicin, was less toxic, and triggered less multidrug resistance.
Doxorubicin-resistant uveal melanoma
The conjugate slowed the growth of a doxorubicin-resistant uveal melanoma cell line and was taken up through LHRH receptors, even where only receptor splice variants were expressed.
Uveal melanoma genes
In uveal melanoma cells, the conjugate switched on the tumour suppressor MASPIN more strongly than free doxorubicin and turned down HIF-1α.
Dosing Data
Zoptarelin doxorubicin was never approved. These are the doses used in its published trials.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
What a Buyer Needs to Know
What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.
What is sold
Unknown: we hold no regulator's label that says in what form Zoptarelin Doxorubicin is supplied. It is prepared and given by clinical staff, not bought and mixed at home: the next part says where.
Mixing a vial: a worked example
Nothing to mix at home, and no syringe units to work out: Zoptarelin Doxorubicin is prepared and given by clinical staff, by a cancer team in hospital.
In the carded trial it was infused into a vein every three weeks as cancer chemotherapy.
Source: PMID 24713545 (a study carded under Research below).
Storage before and after mixing
Unknown: no label on file says how Zoptarelin Doxorubicin is stored. It is kept and prepared by the hospital or clinic that gives it (see the part above); the home rules for a mixed vial in the mixing guide do not apply to it.
How it is taken
As it was given in human studies: Intravenous infusion (Every 3 weeks; Phase 2: platinum-resistant ovarian cancer).
Source: Used in human trials: the route and frequency of each row in Dosing Data below.
What to expect, and when
How long it stays in the body: not established by a measurement cited on this entry.
How long the doses were given: Phase 2: platinum-resistant ovarian cancer: Until progression; Phase 2: castration- and taxane-resistant prostate cancer: Until progression.
When effects appear: unknown; no source on this page gives a time to effect for Zoptarelin Doxorubicin. Results reported in the studies are under Published Research.
Source: Used in human trials, the duration of each row in Dosing Data below.
Side effects, and when to stop or get help
From the Side Effects section: Neutropenia (grade 3-4 in 12% in endometrial cancer); Leucopenia (grade 3-4 in 9%). Full list and cautions ↓
When to stop or get help: unknown; no label or trial on file sets rules for stopping Zoptarelin Doxorubicin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.
Source: the Side Effects section below (“From the phase 2 trials above”).
Interactions
Unknown: a PubMed search for human interaction studies of Zoptarelin Doxorubicin (reviewed 2026-10-03) found none. Unknown is not the same as safe to combine.
Every peptide's record, with its source: the interaction matrix.
Checking what you bought
Unknown: no published independent test of Zoptarelin Doxorubicin products is in our lab-results database yet, so how products sold under this name measure up is not known.
To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Zoptarelin Doxorubicin's expected mass, 1,893.0 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.
Legal status
US: Discontinued (Never approved). Sport: Prohibited (S0 catch-all).
Country by country ↓ · Regulatory tracker
Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.
Side Effects & Contraindications
Reported Side Effects
From the phase 2 trials above.
Contraindications & Cautions
There is no label; trials excluded these patients.
Legal Status
Zoptarelin doxorubicin was never approved.
Frequently Asked Questions
?What is zoptarelin doxorubicin?
An investigational conjugate of the hormone analogue [D-Lys6]LHRH and the chemotherapy drug doxorubicin, meant to deliver doxorubicin to cancers that carry LHRH receptors.
?Did it work?
It produced responses in phase 2 trials in endometrial, ovarian and prostate cancer, but in a 511-patient phase 3 trial in endometrial cancer it was not superior to doxorubicin alone.
?How is it related to leuprolide and other LHRH drugs?
Leuprolide, goserelin and triptorelin are LHRH analogues used to suppress sex hormones. Zoptarelin doxorubicin uses a similar analogue only as a homing signal to carry chemotherapy into receptor-positive cells.
?What dose of zoptarelin doxorubicin was used?
267 mg/m² intravenously every three weeks in the ovarian and endometrial trials, and 210 mg/m² every three weeks in prostate cancer, where neutropenia limited the dose.
?Why did it look so good in mice?
Mouse studies used tumour lines chosen because they carry LHRH receptors, and the conjugate often beat free doxorubicin. The phase 3 trial did not require receptor testing and found it no better than doxorubicin.
References
- [other] PubChem CID 16134409, Zoptarelin doxorubicin: formula C91H117N19O26, molecular weight 1893.0. Read October 3, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/16134409
- [fda] FDA. Drugs@FDA (openFDA): no application on record for zoptarelin doxorubicin. Read October 3, 2026.
- [registry] ClinicalTrials.gov API v2, read October 3, 2026: NCT01767155 (phase 3 second-line endometrial cancer, 511, completed), NCT00569257 (phase 2, 85, completed), NCT01240629 (phase 1/2 prostate, 43, completed), NCT01698281 (phase 2 triple-negative breast, 7, terminated), NCT01234519 (phase 1/2 urothelial, 12, terminated).
- [clinical-trial] Emons G, et al. "Efficacy and safety of AEZS-108 (LHRH agonist linked to doxorubicin) in women with advanced or recurrent endometrial cancer expressing LHRH receptors: a multicenter phase 2 trial (AGO-GYN5)." Int J Gynecol Cancer, 2014;24(2):260-5. PMID: 24418927.
- [clinical-trial] Emons G, et al. "Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5)." Gynecol Oncol, 2014;133(3):427-32. PMID: 24713545.
- [clinical-trial] Yu SS, et al. "A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer." Clin Genitourin Cancer, 2017;15(6):742-749. PMID: 28668277.
- [pubmed] Emons G, et al. "Dose escalation and pharmacokinetic study of AEZS-108 (AN-152), an LHRH agonist linked to doxorubicin, in women with LHRH receptor-positive tumors." Gynecol Oncol, 2010;119(3):457-61. PMID: 20828803.
- [pubmed] Emons G, et al. "The Role of Gonadotropin-Releasing Hormone (GnRH) in Endometrial Cancer." Cells, 2021;10(2). PMID: 33535622.
- [clinical-trial] Liu SV, et al. "Phase I, dose-escalation study of the targeted cytotoxic LHRH analog AEZS-108 in patients with castration- and taxane-resistant prostate cancer." Clin Cancer Res, 2014;20(24):6277-83. PMID: 25278449.
- [pubmed] Hanke N, et al. "A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis." Cancer Chemother Pharmacol, 2018;81(2):291-304. PMID: 29204687.
- [pubmed] Popovics P, et al. "Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels." Oncotarget, 2014;5(12):4567-78. PMID: 24994120.
- [pubmed] Seitz S, et al. "Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125." BMC Cancer, 2014;14:847. PMID: 25410881.
- [pubmed] Gründker C, et al. "Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells." J Obstet Gynaecol Res, 2019;45(7):1334-1342. PMID: 31016845.
- [pubmed] Szepeshazi K, et al. "Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108." Oncotarget, 2013;4(5):751-60. PMID: 23744510.
- [pubmed] Jaszberenyi M, et al. "Inhibition of U-87 MG glioblastoma by AN-152 (AEZS-108), a targeted cytotoxic analog of luteinizing hormone-releasing hormone." Oncotarget, 2013;4(3):422-32. PMID: 23518876.
- [pubmed] Szepeshazi K, et al. "Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108]." Oncotarget, 2012;3(7):686-99. PMID: 22824624.
- [pubmed] Oláh G, et al. "Experimental therapy of doxorubicin resistant human uveal melanoma with targeted cytotoxic luteinizing hormone-releasing hormone analog (AN-152)." Eur J Pharm Sci, 2018;123:371-376. PMID: 30076951.
- [pubmed] Fodor K, et al. "The targeted LHRH analog AEZS-108 alters expression of genes related to angiogenesis and development of metastasis in uveal melanoma." Oncotarget, 2020;11(2):175-187. PMID: 32010430.
Sources & Citations
Studies were read from their PubMed abstracts, October 2026.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.